Skip to content

Study to evaluate the Efficacy and Safety of a topical Unani Formulation in the Management of Eczema

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Efficacy and Safety of a topical Unani Formulation in the Management of NÄ?r FÄ?rsÄ« (Eczema) - CSUNF

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050218
Enrollment
60
Registered
2023-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Habb-e-Akuta: In sufficient quantity to be crushed and mixed with equal quantity of Pure Ghee to make Tila (liniment) and applied topically on the affected site once daily for the perio

Sponsors

National Research Institute of Unani Medicine For Skin Disorders
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants having the following signs and symptoms of disease: Itching, History of Asthma / hay fever in 1st degree relatives, Visible flexural eczema, Excoriation, Burning sensation, Lichenification, Crusting, Dry skin. 2. Participants who are able and willing to comply with the protocol and to sign ICF 3. Chronicity of more than 6 months and less than 2 years

Exclusion criteria

Exclusion criteria: 1.Participants aged Less than 18 years and more than 65 years 2. Known cases of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc. 3. Any other clinical condition that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the trial. 4. Pregnancy and Lactation 5. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients 6. Participants with active alcohol intake and/or drug abuse 7. Participants not willing to sign the ICF and to attend treatment schedule regularly.

Design outcomes

Primary

MeasureTime frame
25% change in appearance and symptomatic relief will be considered significantTimepoint: 42 days

Secondary

MeasureTime frame
Digital photography of all lesions will be done using conditions (fixed room, fixed lighting and fixed camera settings )Timepoint: 42 days

Countries

India

Contacts

Public ContactMariyam Muzaffer

National Research Institute of Unani Medicine For Skin Disorders

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026